Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Organon & Co Profil



BörsenkürzelOGN

Name des UnternehmensOrganon & Co

IPO-datumMay 14, 2021

CEOMorrissey (Joseph T)

Anzahl der mitarbeiter10000

WertpapierartOrdinary Share

GeschäftsjahresendeMay 14

Addresse30 Hudson Street

StadtJERSEY CITY

BörseNASDAQ OMX NASDAQ Basic NYSE

LandUnited States of America

Postleitzahl07302

Telefon15514306000

Websitehttps://www.organon.com/

BörsenkürzelOGN

IPO-datumMay 14, 2021

CEOMorrissey (Joseph T)

Führungskräfte von Organon & Co



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

101.67K

+4.83%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

101.67K

+4.83%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

101.67K

+4.83%

Mr. Kirke Weaver

Executive Vice President, General Counsel, Corporate Secretary

92.70K

+0.06%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.75K

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

116.52K

+0.36%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Organon & Co?



Die fünf größten Anteilseigner von Organon & Co sind: Mr. Matthew M. (Matt) Walsh

Wie viele Institutionen halten Anteile an Organon & Co (OGN)?



Mit Stand vom 2026Q1 halten 1398 Institutionen Anteile an Organon & Co, mit einem Gesamtmarktwert von etwa 239.27M, was 91.12% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -3985201.00 gestiegen.

Was ist die größte Einnahmequelle von Organon & Co?



Am 2026Q1 erzielte das Geschäft mit Women’s Health für Organon & Co den höchsten Umsatz in Höhe von 419.00M, was 26.89% des Gesamtumsatzes entspricht.